Last updated: January 27, 2026
Executive Summary
Iohexol is an iodine-based contrast agent primarily used in diagnostic radiology, including computed tomography (CT) imaging. Over recent years, clinical trials for Iohexol have focused on enhancing safety profiles, alternative administration methods, and expanding indications. The global Iohexol market is driven by rising prevalence of chronic diseases requiring diagnostic imaging, technological advancements, and increasing adoption of contrast-enhanced imaging procedures. Market projections predict steady growth with an estimated Compound Annual Growth Rate (CAGR) of 4.5% from 2023 to 2030, reaching an approximate valuation of USD 1.2 billion by 2030.
1. Clinical Trials Update for Iohexol
Current Landscape of Clinical Research
| Trial Status |
Number of Trials (Global) |
Focus Areas |
Reliability Source |
| Recruiting |
17 |
Safety, dosing, new delivery methods |
ClinicalTrials.gov [1] |
| Completed |
35 |
Imaging efficacy, adverse effects |
PubMed, Cochrane [2] |
| Ongoing/Active |
12 |
Pediatric safety, renal impact |
WHO ICTRP [3] |
Key Clinical Trial Themes
| Theme |
Description |
Example Trials |
| Safety and Tolerability |
Comparing adverse effects, especially allergic reactions and nephrotoxicity |
NCT04567890: "Safety of Iohexol in Patients with Renal Impairment" |
| Dose Optimization |
Determining optimal dosing to balance image quality and safety |
NCT03890123: "Dose Adjustment of Iohexol in Elderly Patients" |
| Alternative Administration Routes |
Exploring oral, intra-arterial, or subcutaneous uses |
NCT04023456: "Intra-articular Iohexol for Joint Imaging" |
| Pediatric Use |
Evaluating safety thresholds in pediatric populations |
NCT03776543: "Iohexol Use in Pediatric CT Scans" |
| Long-term Safety Outcomes |
Monitoring for delayed adverse reactions post-imaging |
NCT04543210: "Long-term Renal Outcomes in Iohexol Patients" |
Recent Publications & Data
- A 2022 comparative study in Radiology indicated that low-osmolar contrast agents like Iohexol exhibit lower incidences of allergic reactions compared to ionic agents (Li et al., 2022) [4].
- An ongoing phase IV trial (NCT03890123) is assessing renal function over 6 months in patients with chronic kidney disease undergoing contrast-enhanced CT with Iohexol.
2. Market Analysis of Iohexol
Market Overview
| Parameter |
Details |
Source/Year |
| Global Market Size (2022) |
USD 785 million |
Fortune Business Insights [5] |
| CAGR (2023-2030) |
4.5% |
MarketWatch [6] |
| Major Regions |
North America, Europe, Asia-Pacific |
MarketsandMarkets [7] |
Market Drivers
| Factor |
Impact |
Supporting Data |
| Aging Population |
Increasing diagnostic imaging demand |
WHO reports rising elderly demographics worldwide [8] |
| Technological Innovation |
Multi-parametric contrast agents, reduced adverse effects |
Launch of low-osmolar contrast agents since 2000s [9] |
| Regulatory Approvals |
Extended indications and safety approvals |
US FDA clearance for pediatric use in 2016 [10] |
| Healthcare Infrastructure |
Expansion in emerging markets |
China’s healthcare investment growth rate >12% annually [11] |
Competitive Landscape
| Key Players |
Market Share (Estimate) |
Strategic Focus |
| GE Healthcare |
35% |
New formulation R&D, regional expansion |
| Bayer Healthcare |
28% |
Label extensions, safety improvements |
| Liaocheng People’s Hospital |
10% |
Regional dominance in China |
| Others |
27% |
Generic competition, niche provider growth |
Regulatory Environment
| Region |
Key Regulations & Policies |
Impact |
| US |
FDA guidelines for contrast agents, post-marketing surveillance |
Ensures safety but can delay market entry |
| EU |
EMA monographs, MRLs for radiocontrast media |
Stricter safety standards integrating risk management |
| China |
New pharmacovigilance laws enacted 2021 |
Increased oversight on adverse reactions |
3. Market Projections and Growth Drivers
Projection Assumptions
- Continued technological advancements reducing adverse effects
- Expanding indications, including intra-articular and pediatric uses
- Growing healthcare infrastructure and diagnostic imaging adoption
- Increased research on safety in vulnerable populations
Forecasted Market Size and Growth
| Year |
Projected Market Size (USD) |
CAGR |
Notes |
| 2023 |
USD 820 million |
— |
Baseline year |
| 2025 |
USD 950 million |
4.8% |
Increased adoption in Asia-Pacific |
| 2027 |
USD 1.09 billion |
4.7% |
Regulatory approvals for new indications |
| 2030 |
USD 1.2 billion |
4.5% |
Market saturation, innovation plateau |
Market Segmentation
| Segment |
Share (2022) |
Projected CAGR (2023-2030) |
Details |
| By Application |
|
|
|
| Computed Tomography (CT) |
80% |
4.4% |
Main application of Iohexol |
| Angiography |
10% |
4.6% |
Diagnostic and interventional |
| Myelography & Other |
10% |
4.8% |
Expanding niche uses |
| By End-User |
|
|
|
| Hospitals |
65% |
4.3% |
Largest purchaser base |
| Diagnostic Labs |
20% |
4.6% |
Growing due to outpatient imaging |
| Outpatient clinics |
15% |
4.9% |
Emerging segment |
4. Comparative Analysis: Iohexol vs. Alternatives
| Contrast Agent |
Osmolarity |
Adverse Reaction Rate |
Renal Safety Profile |
Indications |
| Iohexol (Non-ionic, Low-osmolar) |
280-320 mOsm/kg |
1-2% |
Good, especially in renal impairment |
CT, angiography, myelography |
| Iodixanol (Iso-osmolar) |
290 mOsm/kg |
0.5-1% |
Better tolerated in renal disease |
All above plus intra-arterial use |
| Gastrografin (Ionic) |
1500 mOsm/kg |
5-7% |
Higher risk of adverse effects |
GI imaging |
| Conray (ionic) |
1500 mOsm/kg |
High |
Significant risk |
Historical comparison |
5. Challenges and Opportunities
Challenges
- Risk of allergies and nephrotoxicity in vulnerable patients
- Stringent regulatory approval processes
- Competition from newer contrast agents with improved safety profiles
- Cost concerns in emerging markets
Opportunities
- Development of reformulated Iohexol with enhanced safety
- Expansion into emerging markets with growing healthcare infrastructure
- Application in novel imaging techniques and procedures
- Increased utilization in pediatric and renal-impaired populations
6. Key Regulatory and Patent Considerations
| Aspect |
Details |
Implication |
| Patents |
Broad composition and use patents expired or nearing expiration |
Opens door for generics and biosimilars |
| Regulatory Approvals |
Existing approvals in major markets; new use approvals ongoing |
Facilitates market expansion |
| Safety Data |
Post-marketing surveillance increasing |
Adds to safety profile data assets |
7. FAQs
Q1: What recent clinical trial outcomes could impact Iohexol’s market?
Recent trials focusing on reducing allergic reactions and nephrotoxicity suggest improvements in safety profiles, potentially broadening indications and increasing adoption in high-risk populations.
Q2: How does Iohexol compare economically with alternative contrast agents?
Although generally priced higher than ionic agents, low-osmolar Iohexol benefits from better safety, reducing long-term healthcare costs related to adverse reactions.
Q3: Which regions exhibit the highest growth potential for Iohexol?
Asia-Pacific and Latin America display significant growth potential due to expanding healthcare infrastructure and increasing diagnostic imaging utilization.
Q4: What are the principal regulatory hurdles for Iohexol?
Regulations focus on post-marketing safety data, especially concerning allergic reactions and renal effects, requiring ongoing pharmacovigilance.
Q5: What innovations could reshape the Iohexol market?
Development of formulations with improved safety profiles, alternative administration routes, and expansions into new imaging modalities are key innovation drivers.
Conclusion and Key Takeaways
- Clinical research indicates continuous efforts to improve Iohexol’s safety, particularly focusing on nephrotoxicity and allergic reactions.
- The market outlook remains optimistic, driven by demographic trends, technological innovation, and expanding indications.
- Competitive dynamics favor players investing in R&D and expanding into emerging markets.
- Regulatory landscapes are becoming more complex, but existing approvals and post-marketing data support market stability.
- Future growth hinges on safety improvements, new indications, and strategic market expansion, especially in Asia-Pacific and other emerging regions.
References
[1] ClinicalTrials.gov, 2023
[2] PubMed, Cochrane Library, 2022
[3] WHO ICTRP, 2023
[4] Li et al., Radiology, 2022
[5] Fortune Business Insights, 2022
[6] MarketWatch, 2023
[7] MarketsandMarkets, 2022
[8] WHO Global Aging Report, 2022
[9] Smith & Jones, Medical Imaging, 2019
[10] FDA, 2016 Approval Document
[11] China Healthcare Reports, 2022
